Skip to main content

Vyvgart Hytrulo News

FDA Approves Self-Injection of Vyvgart Hytrulo

WEDNESDAY, April 16, 2025 – The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult...

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefilled Syringe for Self-Injection

April 10, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S....

Argenx Announces FDA Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Amsterdam, the Netherlands June 21, 2024 -- argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...

FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use in Generalized Myasthenia Gravis

SAN DIEGO, June 20, 2023 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for Vyvgart...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Myasthenia Gravis

Vyvgart Hytrulo patient information at Drugs.com